

Title: *Mycobacterium tuberculosis* canonical virulence factors interfere with a late component of the TLR2 response.

Authors

Amelia E. Hinman¹, Charul Jani¹, Stephanie C. Pringle¹, Wei R. Zhang¹, Neharika Jain⁴,
Amanda J. Martinot⁴, Amy K. Barczak^{1,2,3,*}

Affiliations

¹ The Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA

² The Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, 02114, USA

³ Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA

⁴ Department of Infectious Diseases and Global Health, Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, 01536

* Correspondence: abarczak@mgh.harvard.edu

16 **Abstract**

17
18 For many intracellular pathogens, the phagosome is the site of events and interactions that
19 shape infection outcome. Phagosomal membrane damage, in particular, is proposed to benefit
20 invading pathogens. To define the innate immune consequences of this damage, we profiled
21 macrophage transcriptional responses to wild-type *Mycobacterium tuberculosis* (Mtb) and
22 mutants that fail to damage the phagosomal membrane. We identified a set of genes with
23 enhanced expression in response to the mutants. These genes represented a late component
24 of the TLR2-dependent transcriptional response to Mtb, distinct from an earlier component that
25 included TNF. Expression of the later component was inherent to TLR2 activation, dependent
26 upon endosomal uptake, and enhanced by phagosome acidification. Canonical Mtb virulence
27 factors that contribute to phagosomal membrane damage blunted phagosome acidification and
28 undermined the endosome-specific response. Profiling cell survival and bacterial growth in
29 macrophages demonstrated that the attenuation of these mutants is partially dependent upon
30 TLR2. Further, TLR2 contributed to the attenuated phenotype of one of these mutants in a
31 murine model of infection. These results demonstrate two distinct components of the TLR2
32 response and identify a component dependent upon endosomal uptake as a point where
33 pathogenic bacteria interfere with the generation of effective inflammation. This interference
34 promotes TB pathogenesis in both macrophage and murine infection models.

35

36 **Introduction**

37 Innate immune recognition of invading pathogens, typically driven by the interaction of
38 pattern recognition receptors (PRRs) and pathogen-associated molecular patterns (PAMPs),
39 requires recognition of microbial products at multiple subcellular sites. While some PRRs
40 recognize PAMPs at a single site within the cell, other PRRs have the potential to bind PAMPs
41 and initiate signaling from multiple sites. The mechanisms through which one PRR can
42 recognize and respond distinctly to PAMPs at different subcellular sites is best understood for
43 TLR4/LPS interactions [1-5]. Although principles elucidated with LPS and TLR4 are broadly
44 thought to hold for other PAMP/PRR interactions, to date we have less insight into subcellular
45 sites of signaling by other PRRs, the contribution of compartment-specific signaling in the
46 response to complex microorganisms, and the pathogenic strategies employed to evade such
47 compartmentalized signaling events.

48 TLR2, a receptor for bacterial cell wall lipoproteins, has been suggested to signal from
49 the plasma membrane and endosomes, similar to TLR4. Endosome-specific TLR2 signaling in
50 response to pathogenic bacteria has been partially explored using the model of *Staphylococcus*

51 *aureus* taken up into macrophages [6]; in that work, TNF release was shown to be partially
52 dependent upon TLR2 and dependent upon endosomal uptake. TLR2 activation has also been
53 described to induce a type I interferon (IFN) transcriptional response from endosomes [7-10].
54 Overall, the mechanisms and physiological contexts in which compartment-specific TLR2
55 signaling occurs are unclear. In particular, it is unknown whether findings with *S. aureus* extend
56 to other infectious agents and whether pathogens use strategies to prevent TLR2 signaling from
57 the plasma membrane or endosomes.

58 *Mycobacterium tuberculosis* (Mtb) represents a model to study potential mechanisms of
59 innate immune evasion, as this pathogen co-evolved with mammals and encodes multiple
60 strategies of host manipulation. Mtb has a complex repertoire of PAMPs, and infection with Mtb
61 is recognized by both membrane-bound and cytosolic PRRs. The specific complement of PRRs
62 that drive the macrophage response to the intact bacterium and the subcellular sites of
63 recognition of those PAMPs have not been clearly defined. The canonical Mtb virulence factors
64 phthiocerol dimycocerosate (PDIM) and ESX-1 contribute to disruption of the macrophage
65 phagosomal membrane upon infection [11-15]; we sought to leverage this shared pathogenic
66 effect to gain insight into compartment-specific signaling in the macrophage response to Mtb.

67 To probe the relationship between Mtb-mediated phagosomal membrane damage and
68 innate immune recognition of infection, we serially profiled the macrophage response to wild-
69 type Mtb or PDIM and ESX-1 Mtb mutants, which fail to damage the phagosomal membrane.
70 We found that the mutants elicited markedly enhanced expression of a cluster of inflammatory
71 genes induced late after infection; expression was strictly dependent upon MYD88 and TLR2.
72 TNF expression and release are commonly used as a marker of TLR activation; however, we
73 found that induction of TNF occurred with an earlier set of TLR2-dependent genes and differed
74 minimally between the response to wild-type Mtb and our mutants. We thus hypothesized that
75 infection with Mtb elicits a two-component TLR2-dependent response, and that the later
76 component of the response is preferentially blunted by Mtb factors that damage the phagosomal
77 membrane. Treatment of macrophages with synthetic TLR2 ligand elicited a similar two-
78 component transcriptional response, suggesting that these components are fundamental facets
79 of TLR2 signaling rather than pathogen-specific. Induction of the early component of the TLR2
80 response was similar in the presence of endosomal uptake inhibitors; in contrast, the later
81 component was markedly diminished by inhibition of endosomal uptake. Induction of the
82 endosome-specific response was dependent upon phagosome acidification. We found that Mtb
83 factors known to damage the phagosomal membrane contributed to Mtb-induced limitation of
84 phagosome acidification, which in turn limited production of the late component of the TLR2

85 response. Consistent with published reports, PDIM-mutant and ESX-1-mutant Mtb had
86 attenuated virulence phenotypes in wild-type macrophages, with reduced macrophage
87 cytotoxicity and reduced bacterial growth. Both of these attenuated phenotypes were partially
88 reversed in TLR2^{-/-} macrophages, suggesting that TLR2-dependent responses contribute to the
89 attenuation of these mutants. As expected, PDIM-mutant Mtb had attenuated infection
90 phenotypes in C57BL/6J mice, with reduced bacterial growth and lung infiltrates. In contrast, in
91 TLR2^{-/-} mice PDIM-mutant Mtb grew more robustly and caused pulmonary infiltrates more
92 similar to wild-type Mtb. These results support a model in which PDIM and ESX-1 contribute to
93 Mtb virulence in part by blunting a protective endosome-specific component of the TLR2-
94 dependent response to infection.

95

96

97 **Results**

98 *Macrophage infection with Mtb PDIM or ESX-1 mutants elicits enhanced expression of an*
99 *inflammatory transcriptional program*

100 The Mtb ESX-1 protein secretion system has long been known to mediate phagosomal
101 membrane damage [13, 15]; the mycobacterial lipid phthiocerol dimycocerosate (PDIM) was
102 more recently found to play a similar role in infection [11, 12, 14]. To understand how the
103 capacity to damage the phagosomal membrane shapes the innate immune response to Mtb, we
104 sought to leverage the similar effects of PDIM and ESX-1-mediated secretion within the
105 macrophage. We thus compared the response to wild-type Mtb with the response to PDIM and
106 ESX-1 mutants, with the goal of identifying facets of the macrophage response to Mtb impacted
107 by phagosomal membrane damage. To enable meaningful comparison, we first tested whether
108 wild-type Mtb, PDIM mutants, and ESX-1 mutants were taken up similarly into bone marrow-
109 derived macrophages (BMDM). While the possibility of PDIM facilitating uptake into
110 macrophages has been raised [16, 17], using either CFU or flow cytometry we found that wild-
111 type Mtb strain H37Rv, PDIM mutants, and ESX-1 mutants were taken up at similar rates
112 **(Supp. Fig. S1A-B)**.

113 To define the macrophage transcriptional programs induced by Mtb, we infected BMDM
114 with wild-type Mtb and performed comprehensive transcriptional profiling at 4, 8, 12, and 16
115 hours post-infection **(Supp. Table 1)**. Focusing on the 907 genes changed two-fold upon
116 infection, genes could be categorized into three clusters with distinct patterns of expression
117 **(Fig. 1A)**. Cluster 1 genes were progressively induced, and cluster 2 genes were progressively
118 repressed over time after infection. Cluster 3 genes were induced upon infection and peaked at

119 8-12 hours before waning. To identify the facets of the macrophage response most impacted by
120 phagosomal membrane damage, we next compared this baseline response to wild-type Mtb
121 with the response to PDIM or ESX-1 mutants (**Supp. Table 1**). For this comparison, we used
122 PDIM mutants we had demonstrated in previous work to lack PDIM production (Δmas and
123 $\Delta ppsD$) and an ESX-1 mutant we had demonstrated lacked ESX-1 secretion but produced and
124 properly localized PDIM ($Tn::eccCa1$) [12]. Comparing the macrophage response to our
125 mutants with the response to wild-type Mtb, we found that expression of genes in clusters 2 and
126 3 was similar in response to each of the three strains. In contrast, expression of genes in cluster
127 1 was markedly impacted by loss of PDIM or ESX-1. However, not all genes in the cluster
128 responded similarly to the mutants; classifying genes in this cluster based on their response to
129 PDIM and ESX-1 mutants clearly distinguished two subclusters (**Fig. 1B**). Induction of genes in
130 subcluster 1A was markedly diminished in response to PDIM and ESX-1 mutants relative to
131 wild-type Mtb (**Fig. 1B**). Ingenuity Pathway Analysis [18] of genes in this subcluster predicted
132 STAT1, IRF3, interferon- α , and IFNAR as upstream regulators with high confidence, suggesting
133 that these genes comprised the type I IFN response. Manual inspection confirmed that
134 interferon stimulated genes were highly represented in subcluster 1A. These results were
135 consistent with previous work demonstrating that the macrophage type I IFN response to Mtb is
136 dependent upon ESX-1-mediated secretion [19] and PDIM [12].

137 In contrast to subcluster 1A, expression of genes in subcluster 1B was enhanced in
138 response to PDIM or ESX-1 mutants relative to wild-type Mtb at later timepoints (**Fig. 1C-D, Fig.**
139 **2A**). Strikingly, this subcluster included multiple genes important for the host response to Mtb,
140 including MARCO [20], prostaglandin E synthase [21-24], lipocalin 2 [25, 26], Irg1 [27, 28] and
141 matrix metalloproteinase 14 [29]. The kinetics of overall induction and enhanced expression
142 observed in response to the PDIM and ESX-1 mutants were independent of MOI, as the same
143 patterns were observed infecting with MOI 2:1 and 10:1 (**Figs. 2A-B**). Enhanced expression
144 was similarly elicited in BALB/c BMDM, suggesting that the enhanced response is independent
145 of the background genetic inflammatory state of the cells (**Supp. Fig. S1C**). Enhanced
146 expression was observed regardless of the specific PDIM or ESX-1 mutation, including ESX-1
147 core complex mutant $Tn::eccCa1$, secreted effector mutants ($\Delta esxB$ and $Tn::espC$), mutants in
148 the synthetic pathway for distinct components of PDIM (Δmas and $\Delta ppsD$), and a PDIM
149 transport mutant ($Tn::drrC$) (**Fig. 2C**). Complementation of the disrupted ESX-1 or PDIM gene
150 restored expression to wild-type levels (**Fig. 2D**). PDIM and ESX-1 mutants are both known to
151 be attenuated for growth in macrophages [30, 31]; we thus considered the possibility that any
152 attenuated mutant would elicit enhanced expression of subcluster 1B genes. To test this

153 possibility, we obtained a well-characterized Mtb mutant. The deleted gene, $\Delta pckA$, catalyzes
154 the first step in gluconeogenesis, and the mutant is highly attenuated for growth in macrophages
155 [32] (**Supp. Fig. S1D**). Infection with the $\Delta pckA$ mutant did not elicit enhanced expression of
156 subcluster 1B genes (**Supp. Fig. S1E**), demonstrating that the enhanced response to PDIM or
157 ESX-1 mutants is not a general response to mutants with impaired intracellular survival. These
158 results suggest that PDIM and ESX-1 functions blunt induction of an inflammatory
159 transcriptional program that includes multiple genes individually linked to control of TB infection.
160

161 *PDIM and ESX-1 blunt the later component of a biphasic TLR2-dependent transcriptional*
162 *response to Mtb.*

163 Ingenuity Pathway Analysis of genes in subcluster 1B predicted MYD88 and NF- κ B as
164 upstream regulators. To test these predictions and define upstream regulators, we profiled
165 expression in BMDM from knockout mice. Consistent with pathway predictions, expression in
166 response to either wild-type Mtb or the mutants was lost in MYD88^{-/-} BMDM (**Fig. 3A**). MYD88
167 functions as a signaling adapter for TLRs; we next sought to identify the relevant upstream TLR.
168 Mtb produces multiple potential TLR2 antigens [33-39]; we thus tested a role for TLR2 as the
169 relevant upstream TLR. Similar to findings for MYD88, expression of representative genes upon
170 infection with wild-type Mtb or PDIM or ESX-1 mutants was entirely lost in TLR2^{-/-} BMDM (**Fig.**
171 **3A**). In contrast, TLR4^{-/-} knockout BMDM responded similarly to wild-type BMDM (**Fig. 3B**).
172 These results confirmed MYD88 and TLR2 as upstream regulators of macrophage
173 transcriptional response component blunted by PDIM and ESX-1 function.

174 Given the preponderance of work using TNF as a marker of TLR activation, we next
175 examined the relationship between TLR2, TNF expression, and PDIM and ESX-1 in the
176 macrophage response to Mtb. TNF did not cluster with 1B genes; instead TNF was in cluster 3
177 (**Fig. 1A**) together with genes minimally impacted by PDIM and ESX-1. Our RNAseq data
178 additionally demonstrated that expression of TNF peaked earlier post-infection than expression
179 of subcluster 1B genes and then waned. At an MOI of 2:1, we found that induction of TNF was
180 very modest (less than two-fold at the time of peak induction, **Fig. 3C**), limiting our ability to reliably
181 any decrease in TNF expression. Infection at an MOI of 10:1 modestly enhanced expression of
182 TNF and delayed the time of peak expression (**Fig. 3D**). At both MOI 2:1 and 10:1, we found that
183 TNF expression was very modestly impacted by PDIM and ESX-1 (**Fig. 3C-D**). MOI of 5:1 gave
184 similar kinetics and magnitude of TNF expression to MOI of 10:1 (**Supp. Fig. S2A**); we thus
185 selected an MOI of 5:1 to minimize macrophage cell death while allowing us to reliably measure
186 any impact of experimental interventions on TNF expression. TNF expression was partially lost in

187 TLR2 and MYD88 knockout BMDM (**Fig. 3E**), suggesting that additional PRRs likely contribute to
188 TNF expression in the response to Mtb. We hypothesized that TNF was part of a broader early
189 TLR2-dependent transcriptional program; clustering genes across all infection conditions
190 identified 17 genes with expression highly correlated with TNF (**Supp. Fig. S2B**). Testing
191 expression of an additional representative gene from that cluster, NFKbiz, confirmed a pattern of
192 expression similar to TNF. Similar to TNF, expression was minimally impacted by PDIM and ESX-
193 1 and was partially dependent upon MYD88 and TLR2 (**Fig. 3C-E**). For Mtb infection of
194 macrophages, TNF transcription and release have been described as potentially dissociated [40].
195 However, we found that similar to TNF transcription, TNF release upon Mtb infection was partially
196 dependent upon MYD88 and TLR2 (**Fig. 3F**) and very modestly increased upon infection with
197 PDIM- or ESX-1-mutant Mtb (**Fig. 3G**). Our results thus suggest that Mtb infection of
198 macrophages induces distinct early and late TLR2-dependent transcriptional responses, and that
199 canonical Mtb virulence factors that interfere with phagosomal membrane integrity preferentially
200 blunt the later response.

201

202 *The observed biphasic transcriptional response is a fundamental feature of TLR2 signaling.*

203 We reasoned that the two-component TLR2 response we observed upon Mtb infection
204 either could be pathogen-specific or could reflect a fundamental feature of TLR2 signaling. To
205 distinguish between these possibilities, we treated BMDM with PAM3CSK4 or PAM2CSK4,
206 synthetic agonists of TLR1/TLR2 and TLR2/TLR6, respectively, and profiled expression of genes
207 representative of the early and late TLR2-dependent response to Mtb. Treatment with either
208 synthetic ligand elicited expression of genes in the early component of the TLR2-dependent
209 response to Mtb with a similar pattern of expression, peaking at 2-4 hours post-treatment before
210 waning (**Fig. 4A, Supp. Fig. S3A**). PAM3CSK4 or PAM2CSK4 also elicited expression of genes
211 in the later TLR2-dependent response component with delayed kinetics, evident by 4 hours post-
212 infection but continuing to increase through 24 hours (**Fig. 4B, Supp. Fig. S3B**). As with Mtb
213 infection, synthetic ligand-dependent expression of genes representative of both the early and
214 late clusters was dependent upon TLR2 and the signaling adapter MYD88 (**Fig. 4C-D**). PIM6 has
215 been described to be the most potent TLR2 agonist in the Mtb PAMP repertoire [41]; we found
216 that treating BMDM with purified PIM6 similarly induced the early and late response genes in a
217 TLR2-dependent manner (**Fig. 4E-F**). The two observed components of the TLR2-dependent
218 response to Mtb infection thus appear to reflect inherent dynamics of TLR2 signaling in
219 macrophages rather than dynamics specific to recognition of intact Mtb. None of the known

220 adapters TRIF, TRAM, or TIRAP were required for induction of the late response (**Supp. Fig.**
221 **S3C-D**).

222

223 *The later component of the TLR2-dependent transcriptional response requires endosomal*
224 *uptake.*

225 We next considered possible determinants of the two distinct TLR2 response components.

226 We first considered that expression of genes in the later component may be driven by signaling

227 through the TNF receptor initiated by the early component; however, late response component

228 genes were expressed similarly in wild-type and TNF receptor knockout BMDM (**Supp. Fig. S4A**).

229 We then considered alternate hypotheses. PDIM and ESX-1 function preferentially undermine the

230 second component of the response, and both interact with the phagosomal membrane. We thus

231 hypothesized that the determinant of the distinct components may be spatial, with expression of

232 the two sets of genes initiated at distinct subcellular sites. To distinguish between surface-initiated

233 signal and endosome-specific signal, we used the dynamin inhibitor dynasore [42]. Dynamin is

234 required for the final step of formation of the endocytic vesicle, and in the context of LPS

235 recognition by TLR4, dynamin has been used to dissect compartment-specific aspects of

236 signaling [4, 43, 44]. In the context of TLR2 on macrophages, dynamin does not change the

237 surface and endosomal distribution of the receptor, but blocks uptake of PAM3CSK4 into the

238 endosome [45]. We thus used dynasore and PAM3CSK4 to test whether uptake of synthetic TLR2

239 ligand into the endosome is required for activation of either component of the response.

240 PAM3CSK4-induced expression of genes in the early cluster was not significantly changed by

241 dynasore pre-treatment (**Fig. 5A**). In contrast, PAM3CSK4-induced expression of genes in the

242 late cluster was markedly reduced (**Fig. 5B**).

243 We next wanted to test whether the compartment-specificity of the two components of the

244 TLR2-dependent proinflammatory response to synthetic ligand is similar for the response to Mtb.

245 The effect of dynasore on Mtb uptake has not previously been tested; using gentamicin protection

246 assays, we found that dynasore significantly decreased Mtb uptake (**Supp. Fig. S4B-C**). We then

247 tested the effect of inhibiting Mtb uptake on expression of genes in the early and late clusters.

248 Similar to treatment with synthetic ligand, inhibition of Mtb uptake with dynasore left expression

249 of genes in the early TLR2-dependent cluster largely preserved (**Fig. 5C**), but significantly blunted

250 expression of genes in the late cluster (**Fig. 5D**). Results were similar when BMDM were pre-

251 treated with the actin polymerization inhibitor cytochalasin D (**Fig. 5E, Supp. Fig. S4C**), which

252 has previously been used to distinguish innate immune signaling pathways initiated from the cell

253 surface vs. the endosome [6, 7, 9]. Similar to the patterns observed for TNF transcription,

254 dynasore pre-treatment had minimal impact on TNF release (**Fig. 5F**). These results suggest that
255 while expression of early cluster genes can be initiated from the plasma membrane, expression
256 of genes in the later cluster is dependent upon endosomal uptake.

257 Induction of type I IFNs in response to TLR2 activation has been previously linked to
258 endosomal uptake [7-10]. We found that stimulation of BMDM with TLR2 agonists modestly
259 induced type I IFNs (**Supp. Fig. S5A-B**); this induction was dependent upon TLR2 (**Supp. Fig.**
260 **S5C**) and partially inhibited by dynasore pre-treatment (**Supp Fig. S5D**). However, the kinetics
261 and magnitude of induction of IFN- β were distinct from the late pro-inflammatory component of
262 the TLR2 response, suggesting that the endosome-specific pro-inflammatory response is distinct
263 from the type I IFN response. Consistent with established models, induction of the type I IFN
264 response to Mtb was independent of TLR2 (**Supp. Fig. S5E**). Our results suggest that while
265 induction of the second component of the TLR2-dependent response is similar between Mtb and
266 purified or synthetic TLR2 ligand, induction of type I IFNs is not part of this shared response.

267

268 *Full activation of the endosome-specific TLR2 response is dependent upon phagosome*
269 *acidification.*

270 We next sought to understand how PDIM and ESX-1 function might undermine induction
271 of the second component of the TLR2 response. Both PDIM and ESX-1 are required for induction
272 of the type I IFN response to Mtb [12, 19] (**Supp. Fig. 5F**), and interference between induction of
273 type I IFNs and NF- κ B at the transcription factor level has previously been proposed in the
274 macrophage response to other pathogens [46]. We thus hypothesized that PDIM and ESX-1-
275 facilitate induction of type I IFNs, and that type I IFN-activated transcription factors interfere with
276 binding of NF- κ B-dependent transcription factors that contribute to the later component of the
277 TLR2 response. To test this hypothesis, we profiled the macrophage response to Mtb in
278 macrophages unable to mount a type I IFN response to infection. STING is strictly required for
279 the type I IFN response to Mtb upstream of IRF3 activation [13] (**Supp. Fig. S5E**). We predicted
280 that if type I IFN-activated transcription factors blunt the TLR2 response, the response to wild-
281 type Mtb would be increased in STING knockout BMDM relative to wild-type BMDM. We
282 additionally predicted that the response to wild-type Mtb and PDIM or ESX-1 knockouts would be
283 equivalent in STING knockout BMDM, as the type I IFN response would be similarly absent in
284 response to all three Mtb strains. In fact, neither prediction tested correct (**Supp. Fig S5G**),
285 suggesting that the mechanism through which PDIM and ESX-1 blunt the TLR2-dependent
286 response to Mtb is independent of their role in type I IFN induction.

287 We then considered other ways that PDIM and ESX-1 function might interfere with the
288 TLR2 response. Both PDIM and ESX-1 are required for phagosomal membrane damage [11, 13,
289 14]. Candida-mediated phagosomal membrane damage and sterile phagosomal membrane
290 damage have both been described to interfere with phagosome acidification, potentially because
291 of loss of the proton gradient across the membrane at sites of damage [47, 48]. We reasoned that
292 PDIM- and ESX-1-mediated membrane damage might similarly contribute to the known limitation
293 of acidification in Mtb-containing phagosomes. An ESX-1 mutant in *M. marinum* has in fact
294 previously been shown to reside in a more highly acidified macrophage phagosome than wild-
295 type *M. marinum* [49]. Providing suggestive evidence for a link between phagosome acidification
296 and the TLR2 response, inhibitors of phagosome acidification limit the MYD88-dependent
297 response to *Staphylococcus aureus* [6]; this effect was attributed to a requirement for cathepsin
298 activation within acidified lysosomes to process intact *S. aureus* and release TLR agonists. We
299 thus hypothesized that PDIM and ESX-1 mediated membrane damage contributes to the
300 limitation of phagosome acidification, and that limitation then impacts endosome-specific TLR2
301 activation.

302 To first test whether PDIM and ESX-1 function impact phagosome pH, we used the pH-
303 sensitive fluorescent dye pHrodo. pHrodo labeling of Mtb has previously been used to quantify
304 phagosomal pH around the mycobacterium [50]. We labeled PDIM-mutant, ESX-1-mutant, or
305 wild-type Mtb expressing GFP with pHrodo, then infected BMDM. CellProfiler [51] image analysis
306 was used to identify GFP-Mtb; the corresponding pHrodo mean fluorescent intensity for each
307 identified bacterium was then measured (**Supp. Fig. S6A-B**). At 6, 12, or 24 hours post-infection,
308 pHrodo mean fluorescent intensity around PDIM or ESX-1 mutant Mtb was significantly higher
309 than around wild-type Mtb (**Fig. 6A**), suggesting that phagosomes containing PDIM- or ESX-1-
310 mutant Mtb becomes relatively more acidic than phagosomes containing wild-type Mtb.

311 We then tested whether phagosome acidification enhances endosomal TLR2 signaling.
312 We first confirmed that pre-treatment with concanamycin A, which inhibits the vacuolar ATPase,
313 limits phagosome acidification in BMDM using both zymosan beads (**Supp. Fig. S6C**) and
314 infection with pHrodo-labeled PDIM and ESX-1 mutants (**Supp. Fig. S6D**). We then pre-treated
315 BMDM with concanamycin A prior to infection with Mtb. We found that while expression of the
316 early cluster of genes was not significantly changed (**Fig. 6B**), expression of the second cluster
317 of genes was markedly diminished in the presence of concanamycin A (**Fig 6C**). These results
318 suggested that phagosome acidification enhances the endosomal component of the TLR2-
319 dependent response to Mtb. If acidification primarily drives the release of antigens from intact
320 Mtb, as described for *S. aureus* [6], we would expect this acidification to be relevant upon infection

321 with intact bacteria, but dispensable for the response to synthetic TLR2 ligand. Expression of
322 genes in the early component of the response to synthetic TLR2 ligand was not changed by the
323 addition of concanamycin A (**Fig. 6D**). However, expression of genes in the later component of
324 the response was markedly diminished by the addition of concanamycin A (**Fig. 6E**). Similar
325 results were obtained for the Mtb TLR2 ligand PIM6 (**Supp. Fig. S6E-F**). These results suggest
326 that the late component of TLR2 signaling is dependent on phagosome acidification entirely
327 independent of the capacity to process pathogen and release TLR2 agonists. Taken together, our
328 results are consistent with the hypothesis that Mtb-mediated damage of the phagosome
329 membrane blunts the endosome-specific TLR2 response by limiting phagosome acidification.
330 Further, the dependence on phagosome acidification suggests a potential mechanism through
331 which compartment-specific TLR2 signaling is regulated. Signaling of the endosome-restricted
332 TLRs, TLR7 and TLR9, is in fact strictly dependent upon endosomal acid-activated proteases [52,
333 53], offering precedent for pH as a regulator of compartment-specific TLR signaling.

334

335 *PDIM and ESX-1 modulate TLR2-dependent infection outcomes in macrophages*

336 We next sought to understand whether the interaction between PDIM/ESX-1 and TLR2
337 contributes to infection outcomes in macrophages. Mtb infection has been shown to drive
338 macrophage cell death, including apoptosis [54], necrosis [55], and ferroptosis [56]. PDIM has
339 been described to specifically contribute to macrophage necrosis [14]; ESX-1 has also been
340 shown to contribute to macrophage cell death after infection [11, 57]. In one study, pre-treatment
341 of macrophages with a TLR4 or TLR2 agonist reduced Mtb-induced cell death [58]. Consistent
342 with previous reports, we found that in wild-type macrophages PDIM and ESX-1 mutants induced
343 less cell death than wild-type Mtb or complemented mutants (**Fig. 7A-B**). We hypothesized that
344 PDIM/ESX-1 interference with the late component of the TLR2 response might contribute to the
345 cell death induced by wild-type Mtb; in that case, we would expect the enhanced macrophage
346 survival observed upon infection with the PDIM or ESX-1 mutants to be lost or diminished in
347 TLR2^{-/-} macrophages. Infection with wild-type Mtb induced a similar degree of cell death in wild-
348 type and TLR2^{-/-} macrophages. However, the resistance to cell death observed in wild-type
349 macrophages infected with PDIM or ESX-1 mutants was partially lost in TLR2^{-/-} macrophages
350 (**Fig. 7A-B**). These results suggest that PDIM and ESX-1 interference with TLR2-dependent
351 responses contributes to macrophage cell death following infection.

352 We next sought to test whether the interaction between PDIM/ESX-1 and TLR2 impacts
353 Mtb survival and growth in macrophages. PDIM and ESX-1 mutants have an attenuated growth
354 phenotype in macrophages [30, 31]. We hypothesized that if TLR2-dependent responses

355 contribute to this growth restriction, PDIM and ESX-1 mutants should grow more robustly in TLR2-
356 /- BMDM than in wild-type BMDM. Alternatively, if PDIM and ESX-1 mutant growth restriction is
357 entirely independent of TLR2-dependent responses, those mutants should grow similarly in wild-
358 type and TLR2-/- BMDM. Using a low MOI to minimize induction of macrophage cell death, we
359 infected wild-type or TLR2-/- BMDM with our wild-type or mutant Mtb strains. As expected, PDIM
360 and ESX-1 mutants grew less well than wild-type Mtb in C57BL/6J BMDM (**Fig. 7C**). Growth of
361 wild-type Mtb was modestly enhanced in TLR2-/- macrophages relative to wild-type
362 macrophages; further, the PDIM and ESX-1 mutants grew significantly more robustly in the TLR2-
363 /- BMDM than in wild-type BMDM, with growth similar to wild-type Mtb (**Fig. 7C**). These results
364 suggest that TLR2-dependent responses contribute to growth restriction of the PDIM and ESX-1
365 mutants in macrophages. Together with our macrophage survival data, these results indicate that
366 PDIM and ESX-1-mediated interference with TLR2-dependent responses contributes to the
367 pathogenesis of Mtb infection in macrophages.

368

369 *PDIM and ESX-1 modulate TLR2-dependent infection outcomes in mice*

370 Several studies have assessed the role of TLR2 in infection outcomes in mice. Some
371 studies have shown a modest increase in Mtb growth in TLR2-/- mice relative to wild-type mice
372 [59-61], while others have shown no difference in CFU. Most studies have shown increased lung
373 pathology in TLR2 knockout mice, with larger infiltrates, less organization, and more inflammatory
374 cells described as key features in various studies [59, 61, 62]. TLR2-/- mice have been shown to
375 have increased Mtb dissemination to liver and spleen [59] and a more rapid progression to death
376 following infection [59, 62, 63]. In aggregate, these data suggest that TLR2 plays a somewhat
377 modest role in host control of TB infection. We hypothesized that PDIM and ESX-1 interference
378 with the late TLR2-dependent response limits the contribution TLR2 makes to host control of Mtb
379 infection. To test this hypothesis, we compared infection outcomes in wild-type and TLR2-/- mice.
380 As previous profiling had demonstrated that CFU and pathology diverge by 6 weeks post-infection
381 [61], we selected this timepoint for study. A limited number of mutant mice could be obtained for
382 these studies; we thus focused on the interaction between PDIM and TLR2.

383 C57BL/6J and TLR2-/- mice were infected with wild-type, PDIM-mutant, and
384 complemented PDIM-mutant Mtb (**Supp. Fig. S7A**). At the 6-week timepoint, as expected, PDIM-
385 mutant Mtb growth was restricted relative to wild-type Mtb growth in C57BL/6J mice. Wild-type
386 Mtb grew similarly in the lungs of C57BL/6J and TLR2-/- mice. In contrast, PDIM-mutant Mtb had
387 increased growth in the lungs of TLR2-/- mice relative to C57BL/6J mice (**Fig. 7D**), suggesting
388 that PDIM-mediated interference with activation of components of the TLR2-dependent response

389 contributes to the capacity of the bacterium to grow in lung. Histopathologically, the lungs of
390 C57BL/6J mice infected with wild-type Mtb demonstrated defined areas of inflammation by 6
391 weeks post-infection (**Supp. Fig. S7B**), with dense inflammatory infiltrates composed of foamy
392 and non-foamy macrophages and lymphocytes clusters (**Supp. Fig. S7C**). Lungs of C57BL/6J
393 mice infected with PDIM-mutant Mtb showed trends toward fewer areas of inflammation and
394 smaller lesion sizes (**Supp. Fig. S7B**). Examination of the regions of cellular infiltration in mice
395 infected with PDIM-mutant Mtb were notable for similar presence of foamy macrophages and
396 lymphocytes (**Supp. Fig. S7C**). In TLR2^{-/-} mutant mice infected with PDIM-mutant Mtb, infiltrates
397 showed a trend toward more numerous and larger areas of involvement than was observed in
398 C57BL/6J mice (**Supp. Fig. S7B-C**). In total, our data suggest that PDIM modulation of TLR2-
399 dependent responses contributes to pathogenesis *in vivo*. Growth of the PDIM mutant is only
400 partially restored in TLR2^{-/-} mice, indicating that additional mechanisms contribute to the
401 attenuation of PDIM mutants *in vivo*.

402

403 **DISCUSSION**

404 Accumulating data suggest that pathogenic bacteria evolve strategies for evading the
405 components of immunity most critical for controlling their survival and replication. Multiple
406 intracellular pathogens damage the phagosomal membrane in the course of pathogenesis, raising
407 the question of whether this shared function reflects a convergent evolutionary strategy. While
408 phagosomal membrane damage has been proposed to benefit the bacterium in the host-pathogen
409 standoff, the mechanisms through which that benefit might accrue have not been well-established
410 experimentally. In the case of pathogens recognized by TLR2, our results raise the possibility that
411 damaging the phagosomal membrane may serve as a common strategy to limit effective
412 inflammation.

413 Previous work has suggested that TLR2 can signal from the plasma membrane or
414 endosome. Investigation of the mechanisms and consequences of TLR2 signaling has primarily
415 focused on pathogen-specific induction of type I IFNs [7-10] and TNF [6, 64], largely in response
416 to *S. aureus* exposure or viral infection. Our results support a model in which TLR2 activation in
417 fact drives distinct compartment-specific pro-inflammatory transcriptional responses, reflected in
418 both the sets of genes expressed and the kinetics of induction. Although a fundamental feature
419 of TLR2 signaling, the two transcriptional response components are likely to have different
420 relevance in the context of individual infections. In the case of TB, TNF, a component of the early
421 response, is known to be critical for infection control. However, the later response component
422 includes expression of multiple genes demonstrated to be important for both cell intrinsic control

423 of Mtb and priming of the adaptive immune response. Our results demonstrating an interaction
424 between TLR2 and PDIM or ESX-1 for infection outcome suggest that undermining this second
425 component contributes to Mtb's success as a pathogen. More broadly, our results suggest that
426 expanding beyond TNF and type I IFNs as markers of TLR activation may offer both new insights
427 into mechanisms and consequences of TLR signaling and into the links between TLR activation
428 and control of pathogenic infection.

429 Our work suggests one potential mechanism through which PDIM and ESX-1 contribute
430 to the pathogenicity of Mtb. PDIM has previously been shown to interfere with an effective MYD88
431 inflammatory response, as measured by the outcomes of macrophage recruitment to *M. marinum*-
432 containing lesions *in vivo* and iNOS production [65]. In that work, this effect was hypothesized to
433 be attributable to the unmasking of TLR agonists on the mycobacterial surface in the absence of
434 PDIM, an abundant outer membrane lipid. Our results confirm an effect of PDIM on MYD88-
435 dependent inflammation but point toward a different potential molecular interaction between PDIM
436 and inflammation- namely that PDIM limits an endosomal component of the TLR2 response by
437 limiting phagosome acidification. Two lines of evidence support the latter proposed mechanism.
438 First, the effect we observe on TLR2-dependent inflammation is shared between PDIM and ESX-
439 1. ESX-1-mediated secretion is not known to be required for localization of any known TLR2
440 agonist and in fact Mtb has multiple distinct TLR2 ligands; thus the common effect of PDIM and
441 ESX-1 on TLR2-dependent inflammation is unlikely to be due to masking of TLR2 agonists.
442 Second, PDIM and ESX-1 only minimally impact expression of the early TLR2-dependent gene
443 cluster, suggesting that the inherent capacity of TLR2 to "recognize" cognate ligand on the
444 bacterium is similar between wild-type Mtb and ESX-1 or PDIM mutant Mtb.

445 Together with previous work identifying Mtb factors that interfere with TLR2 activation, our
446 work points toward an explanation for the puzzling disparity between the number of identified
447 TLR2 ligands that Mtb possesses and the relatively modest phenotype of Mtb infection in TLR2
448 knockout mice. Work from other groups has identified mycobacterial strategies for interfering with
449 TLR2 activation, primarily studied through an impact on TNF expression and release. The
450 secreted hydrolase Hip1 has been shown to blunt the secretion of cytokines, including TNF- α ,
451 following infection [66]. Recently, the surface lipid sulfolipid-1 was shown to interfere with surface
452 recognition of TLR2 agonists [67]. Our work suggests that the canonical Mtb virulence factors
453 PDIM and ESX-1 function to blunt a distinct, endosome-specific component of the TLR2
454 response, and that this interference in fact modulates infection outcomes in macrophages and in
455 mice. In aggregate, these results suggest that mycobacteria have evolved multiple strategies to
456 undermine TLR2 activation from both the surface and endosome. Adding to the complexity of

457 TLR2-dependent phenotypes in TB infection, studies of the relationship between Mtb TLR2
458 agonists and IFN-g-dependent functions have shown that TLR2 activation can dampen IFN-g-
459 dependent gene expression and cell functions [38, 68]. Ultimately developing new strategies for
460 treating tuberculosis will rely on a deep understanding of the pathogenesis of infection that
461 enables the rational selection of therapeutic targets. Host-directed therapies enhancing the host-
462 protective components of TLR2 activation might offer a path to a more effective inflammatory
463 response to Mtb and ultimately more effective sterilization of TB infection.

Materials and Methods

Bacterial strains and culture

The indicated *Mtb* strains were grown in Middlebrook 7H9 broth (Difco) with Middlebrook OADC (BD), 0.2% glycerol, and 0.05% Tween-80. *Mtb* strains H37Rv, Tn::eccCa1, Δ ppsD, Δ ppsD::pMV261:: Δ ppsD, and Δ mas were characterized in Barczak et al [12]. Tn::espC was grown from a published transposon library in H37Rv [12]. The complement was generated by cloning the espACD operon from H37Rv into the Kpn and XbaI sites of shuttle plasmid pMV261 [69] (F primer atgacagatcggcctagctagg R primer attgtgagcccagtcgggaaa).

Macrophage infections

BMDM were isolated and differentiated in DMEM containing 20% FBS (Cytiva) and 25ng/ml rm-M-CSF (R&D Systems) as previously described [12]. Infections were carried out as previously described [12, 70]. Briefly, *Mtb* strains used were grown to mid-log phase, washed in PBS, resuspended in PBS, and subjected to a low-speed spin to pellet clumps. BMDM were infected at the indicated MOI, allowing 3-4 hours for phagocytosis. Cells were then washed once with PBS, and media was added back to washed, infected cells. The MOI used for each time point was selected to maximize signal while minimizing infection-associated cell death.

Mouse strains

C57BL/6J (Jackson Laboratories strain #000664), BALB/c (Jackson Laboratories strain #000651), *Sting*^{-/-} (C57BL/6J-*Sting*^{gt/J}, Jackson Laboratories strain # 017537), *TLR4*^{-/-} (Jackson Laboratories strain #007227) *Tlr2*^{-/-} (B6.129-*tlr2*^{tm1Kir/J}, Jackson Laboratories strain #004650), *MyD88*^{-/-} (B6.129P2(SJL)-*Myd88*^{tm1.1Defr/J}, Jackson Laboratories strain # 009088), *TNFR*^{-/-} (B6.129S-*Tnfrsf1a*^{tm1lmx} *Tnfrsf1b*^{tm1lmx/J}, Jackson Laboratories strain #003243), and *Trif*^{-/-} (C57BL/6j-*Ticam1*^{Lps2/J}, Jackson Laboratories strain #005037) mice were used for the preparation of bone marrow-derived macrophages.

RNA isolation and qPCR

Infected BMDM were lysed at designated time points following infection with β -ME-supplemented Buffer RLT (Qiagen). RNA was isolated from lysate using an RNEasy kit (Qiagen) supplemented with RNase-free DNase I digest (Qiagen), both according to manufacturer's protocol. cDNA was prepared using SuperScript III (Thermo Fisher Scientific) according to manufacturer's protocol. qPCR was performed using PowerUP SYBR Green (Thermo Fisher Scientific) and primers specific to investigated genes relative to GAPDH control.

RNA-Seq

Poly(A) containing mRNA was isolated from 1 μ g total RNA using NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). cDNA libraries were constructed using NEBNext Ultra II Directional RNA Library Prep Kit for Illumina and NEBNext Multiplex Oligos for Illumina, Index Primers Sets 3 and 4 (New England Biolabs). Libraries were sequenced on an Illumina NextSeq500. Bioinformatic analysis was performed using the open source software GenePattern [59, 63]. Raw reads were aligned to mouse genome using TopHat, and Cufflinks was used to estimate the transcript abundance. FPKM values obtained by Cufflinks were used to plot heatmaps [71]. Three biological replicates for each condition were performed; replicates that failed QC metrics were not included in heatmaps and clustering. K-means clustering was performed in R and functional analysis was performed using IPA [18] (QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis>). RNAseq data is accessible on the NCBI GEO website GSE144330.

TNF ELISAs

BMDM were infected at an MOI of 5:1 as described above. Following a 4 hour phagocytosis, BMDM were washed, and BMDM media was added back. At 24 hours post-infection, supernatants were collected for quantitation of TNF- α using an ELISA Ready-SET-Go! kit according to the manufacturer's protocols. (ThermoFisher Scientific). Four replicates were performed per condition based on the determination that this would give 80% power to detect a 20% difference between samples.

Imaging of pHrodo-labeled bacteria in macrophages

Imaging of pHrodo-labeled Mtb as described in Queval et al. [50]. Mtb strains were grown to mid-log phase, then washed twice with an equal volume of PBS. Mtb was then resuspended in 100mM NaHCO₃ with 0.5M pHrodo dye (Invitrogen) and incubated at room temperature in the dark for 1 hour. The labeled cells were then washed three times with PBS, after which BMDM infections were performed as described above. At the indicated time post-infection, infected BMDM were washed with PBS and fixed in 4% paraformaldehyde. Nuclei were labeled with DAPI (1.25 μ g/ml). Cells were then imaged on a Zeiss Elyra microscope with a 40x oil objective or a TissueFAXS confocal microscope with a 40x objective. Images were imported into CellProfiler [51] for analysis. Bacterial outlines were identified based on GFP signal; the outline was then expanded by 5 pixels, and pHrodo fluorescence intensity within the expanded outline was determined.

CFU quantitation

Bacteria were prepared as described above, and added to BMDM at an MOI of 2:1. After 4 hours, cells were lysed in 0.5% triton X-100, diluted in 7H9 media, and plated on 7H10 plates for colony enumeration. For gentamicin killing assay, cells were treated with dynasore (80 μ M) prior to infection where indicated. Following the 4 hour phagocytosis, cells were washed in PBS with gentamicin (32 μ g/ml), then resuspended in bone marrow macrophage media with gentamicin (32 μ g/ml). After allowing 2 hours for killing of extracellular bacteria, cells were washed, lysed, diluted, and plated for colony enumeration.

Quantitation of MFI for pHrodo-labeled zymosan beads

C57BL/6J BMDM were plated in an 8-chamber slide. Cells were pre-treated with concanamycin A, (50 μ M) or DMSO carrier for 15 minutes. Media was then removed, and pHrodo red zymosan bioparticles (Invitrogen) were added at 0.5mg/ml in BMDM media with concanamycin A or DMSO carrier. After 2 hours, media was removed and cells were washed once with PBS. Cells were then fixed in 4% paraformaldehyde and stained with DAPI (1.25 μ g/ml). Cells were imaged on a Zeiss Elyra PS.1 microscope with a 20x objective. Images were analyzed using a CellProfiler image analysis pipeline. DAPI-stained nuclei were identified and counted and integrated red pHrodo fluorescence was measured for each image.

Macrophage survival assays

C57BL/6J or TLR2^{-/-} BMDM were plated in 96-well format and infected with Mtb strains at an MOI of 5:1. Cells were harvested day 1 and day 5 post-infection using a CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega) in accordance with the manufacturer's instructions. After gentle agitation and 10-minute incubation, wells were read on a Tecan Spark 10M luminescent plate reader. Media was replenished every 48 hours post-infection.

Mouse infections

C57BL/6J (Jackson Laboratories strain #000664) or TLR2^{-/-} (Jackson Laboratories strain # 021302) mice were infected via low dose aerosol exposure with an AeroMP (Biaera Technologies). 3-5 mice per condition were harvested at day 0 to quantify inoculum. 6 weeks

post-infection, mice were euthanized in accordance with AALAC guidelines, and lungs were harvested for CFU and histopathology. Formalin-fixed lungs were embedded in paraffin, sectioned, and stained with hematoxylin and eosin by the MGH histopathology core. Images were acquired on a TissueFAXS slide scanner (TissueGnostics).

Acknowledgements

The authors would like to thank Drs. Roi Avraham, Bryan Bryson, Sarah Fortune, and Jonathan Kagan for critical manuscript review and Dr. Lenette Lu and the laboratories of Drs. Marcia Goldberg and Cammie Lesser for helpful discussions. We would additionally like to thank Dr. Sabine Ehrt for the pckA mutant, parent, and complement strains. The work was funded in part by an MGH Transformative Scholar Award (AKB) and made possible by help from the Harvard University Center for AIDS Research (CFAR), an NIH funded program (P30 AI060354).

Author Contributions

Conceptualization, A.E.H. and A.K.B, Methodology, A.E.H., C.J., and A.K.B., Investigation, A.E.H., C.J., S.C.P., W.R.Z., and A.K.B, Analysis, N.J and A.J.M., Writing, A.E.H., C.J. and A.K.B, Funding Acquisition, A.K.B.

Conflict of Interest

The authors declare no competing interests.

References

1. Bonham KS, Orzalli MH, Hayashi K, Wolf AI, Glanemann C, Weninger W, et al. A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction. *Cell*. 2014;156(4):705-16. doi: 10.1016/j.cell.2014.01.019. PubMed PMID: 24529375; PubMed Central PMCID: PMC3951743.
2. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. *The Journal of experimental medicine*. 2003;198(7):1043-55. doi: 10.1084/jem.20031023. PubMed PMID: 14517278; PubMed Central PMCID: PMC2194210.
3. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. *Cell*. 2006;125(5):943-55. doi: 10.1016/j.cell.2006.03.047. PubMed PMID: 16751103.
4. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. *Nature immunology*. 2008;9(4):361-8. doi: 10.1038/ni1569. PubMed PMID: 18297073; PubMed Central PMCID: PMC4112825.
5. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science*. 2003;301(5633):640-3. doi: 10.1126/science.1087262. PubMed PMID: 12855817.
6. Ip WK, Sokolovska A, Charriere GM, Boyer L, DeJardin S, Cappillino MP, et al. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to *Staphylococcus aureus*. *Journal of immunology*. 2010;184(12):7071-81. doi: 10.4049/jimmunol.1000110. PubMed PMID: 20483752; PubMed Central PMCID: PMC2935932.
7. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. *Nature immunology*.

- 2009;10(11):1200-7. doi: 10.1038/ni.1792. PubMed PMID: 19801985; PubMed Central PMCID: PMC2821672.
8. Dietrich N, Lienenklaus S, Weiss S, Gekara NO. Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. *PloS one*. 2010;5(4):e10250. doi: 10.1371/journal.pone.0010250. PubMed PMID: 20422028; PubMed Central PMCID: PMC2857745.
 9. Musilova J, Mulcahy ME, Kuijk MM, McLoughlin RM, Bowie AG. Toll-like receptor 2-dependent endosomal signaling by *Staphylococcus aureus* in monocytes induces type I interferon and promotes intracellular survival. *The Journal of biological chemistry*. 2019. doi: 10.1074/jbc.RA119.009302. PubMed PMID: 31558608.
 10. Stack J, Doyle SL, Connolly DJ, Reinert LS, O'Keefe KM, McLoughlin RM, et al. TRAM is required for TLR2 endosomal signaling to type I IFN induction. *Journal of immunology*. 2014;193(12):6090-102. doi: 10.4049/jimmunol.1401605. PubMed PMID: 25385819; PubMed Central PMCID: PMC4258402.
 11. Augenstreich J, Arbues A, Simeone R, Haanappel E, Wegener A, Sayes F, et al. ESX-1 and phthiocerol dimycocerosates of *Mycobacterium tuberculosis* act in concert to cause phagosomal rupture and host cell apoptosis. *Cellular microbiology*. 2017;19(7). doi: 10.1111/cmi.12726. PubMed PMID: 28095608.
 12. Barczak AK, Avraham R, Singh S, Luo SS, Zhang WR, Bray MA, et al. Systematic, multiparametric analysis of *Mycobacterium tuberculosis* intracellular infection offers insight into coordinated virulence. *PLoS pathogens*. 2017;13(5):e1006363. doi: 10.1371/journal.ppat.1006363. PubMed PMID: 28505176; PubMed Central PMCID: PMC5444860.
 13. Manzanillo PS, Shiloh MU, Portnoy DA, Cox JS. *Mycobacterium tuberculosis* activates the DNA-dependent cytosolic surveillance pathway within macrophages. *Cell host & microbe*. 2012;11(5):469-80. doi: 10.1016/j.chom.2012.03.007. PubMed PMID: 22607800; PubMed Central PMCID: PMC3662372.
 14. Quigley J, Hughitt VK, Velikovskiy CA, Mariuzza RA, El-Sayed NM, Briken V. The Cell Wall Lipid PDIM Contributes to Phagosomal Escape and Host Cell Exit of *Mycobacterium tuberculosis*. *mBio*. 2017;8(2). doi: 10.1128/mBio.00148-17. PubMed PMID: 28270579; PubMed Central PMCID: PMC5340868.
 15. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, et al. Phagosomal rupture by *Mycobacterium tuberculosis* results in toxicity and host cell death. *PLoS pathogens*. 2012;8(2):e1002507. doi: 10.1371/journal.ppat.1002507. PubMed PMID: 22319448; PubMed Central PMCID: PMC3271072.
 16. Astarie-Dequeker C, Le Guyader L, Malaga W, Seaphanh FK, Chalut C, Lopez A, et al. Phthiocerol dimycocerosates of *M. tuberculosis* participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. *PLoS pathogens*. 2009;5(2):e1000289. doi: 10.1371/journal.ppat.1000289. PubMed PMID: 19197369; PubMed Central PMCID: PMC2632888.
 17. Augenstreich J, Haanappel E, Ferre G, Czaplicki G, Jolibois F, Destainville N, et al. The conical shape of DIM lipids promotes *Mycobacterium tuberculosis* infection of macrophages. *Proceedings of the National Academy of Sciences of the United States of America*. 2019. doi: 10.1073/pnas.1910368116. PubMed PMID: 31757855.
 18. Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523-30. doi: 10.1093/bioinformatics/btt703. PubMed PMID: 24336805; PubMed Central PMCID: PMC3928520.
 19. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. The Type I IFN response to infection with *Mycobacterium tuberculosis* requires ESX-1-mediated secretion and contributes to pathogenesis. *Journal of immunology*. 2007;178(5):3143-52. PubMed PMID: 17312162.

20. Bowdish DM, Sakamoto K, Lack NA, Hill PC, Sirugo G, Newport MJ, et al. Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population. *BMC medical genetics*. 2013;14:47. doi: 10.1186/1471-2350-14-47. PubMed PMID: 23617307; PubMed Central PMCID: PMC3652798.
21. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM, et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. *The Journal of experimental medicine*. 2008;205(12):2791-801. doi: 10.1084/jem.20080767. PubMed PMID: 18955568; PubMed Central PMCID: PMC2585850.
22. Garg A, Barnes PF, Roy S, Quiroga MF, Wu S, Garcia VE, et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human *Mycobacterium tuberculosis* infection. *European journal of immunology*. 2008;38(2):459-69. doi: 10.1002/eji.200737268. PubMed PMID: 18203140; PubMed Central PMCID: PMC2955512.
23. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. *Nature*. 2014;511(7507):99-103. doi: 10.1038/nature13489. PubMed PMID: 24990750; PubMed Central PMCID: PMC4809146.
24. Rangel Moreno J, Estrada Garcia I, De La Luz Garcia Hernandez M, Aguilar Leon D, Marquez R, Hernandez Pando R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. *Immunology*. 2002;106(2):257-66. doi: 10.1046/j.1365-2567.2002.01403.x. PubMed PMID: 12047755; PubMed Central PMCID: PMC1782721.
25. Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T, et al. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. *PloS one*. 2012;7(11):e50052. doi: 10.1371/journal.pone.0050052. PubMed PMID: 23185529; PubMed Central PMCID: PMC3502292.
26. Saiga H, Nishimura J, Kuwata H, Okuyama M, Matsumoto S, Sato S, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. *Journal of immunology*. 2008;181(12):8521-7. doi: 10.4049/jimmunol.181.12.8521. PubMed PMID: 19050270.
27. Hoffmann E, Machelart A, Belhaouane I, Deboosere N, Pauwels A-M, Saint-André J-P, et al. IRG1 controls immunometabolic host response and restricts intracellular *Mycobacterium tuberculosis* infection. *bioRxiv*. 2019:761551. doi: 10.1101/761551.
28. Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, et al. Irg1 expression in myeloid cells prevents immunopathology during *M. tuberculosis* infection. *The Journal of experimental medicine*. 2018;215(4):1035-45. doi: 10.1084/jem.20180118. PubMed PMID: 29511063; PubMed Central PMCID: PMC5881474.
29. Sathyamoorthy T, Tezera LB, Walker NF, Brilha S, Saraiva L, Mauri FA, et al. Membrane Type 1 Matrix Metalloproteinase Regulates Monocyte Migration and Collagen Destruction in Tuberculosis. *Journal of immunology*. 2015;195(3):882-91. doi: 10.4049/jimmunol.1403110. PubMed PMID: 26091717; PubMed Central PMCID: PMC4505956.
30. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of *Mycobacterium tuberculosis* by signature-tagged transposon mutagenesis. *Molecular microbiology*. 1999;34(2):257-67. PubMed PMID: 10564470.
31. Stanley SA, Raghavan S, Hwang WW, Cox JS. Acute infection and macrophage subversion by *Mycobacterium tuberculosis* require a specialized secretion system. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(22):13001-6. doi: 10.1073/pnas.2235593100. PubMed PMID: 14557536; PubMed Central PMCID: PMC240734.
32. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for *Mycobacterium tuberculosis* to establish

- and maintain infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(21):9819-24. Epub 2010/05/05. doi: 10.1073/pnas.1000715107. PubMed PMID: 20439709; PubMed Central PMCID: PMC2906907.
33. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. *Science*. 1999;285(5428):732-6. doi: 10.1126/science.285.5428.732. PubMed PMID: 10426995.
 34. Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. *Journal of immunology*. 2004;173(4):2660-8. doi: 10.4049/jimmunol.173.4.2660. PubMed PMID: 15294983.
 35. Jung SB, Yang CS, Lee JS, Shin AR, Jung SS, Son JW, et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. *Infection and immunity*. 2006;74(5):2686-96. doi: 10.1128/IAI.74.5.2686-2696.2006. PubMed PMID: 16622205; PubMed Central PMCID: PMC1459749.
 36. Nair S, Ramaswamy PA, Ghosh S, Joshi DC, Pathak N, Siddiqui I, et al. The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage. *Journal of immunology*. 2009;183(10):6269-81. doi: 10.4049/jimmunol.0901367. PubMed PMID: 19880448.
 37. Pathak SK, Basu S, Basu KK, Banerjee A, Pathak S, Bhattacharyya A, et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. *Nature immunology*. 2007;8(6):610-8. doi: 10.1038/ni1468. PubMed PMID: 17486091.
 38. Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. *Journal of immunology*. 2006;177(1):422-9. doi: 10.4049/jimmunol.177.1.422. PubMed PMID: 16785538.
 39. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. *Proceedings of the National Academy of Sciences of the United States of America*. 1999;96(25):14459-63. PubMed PMID: 10588727; PubMed Central PMCID: PMC24458.
 40. Shi S, Blumenthal A, Hickey CM, Gandotra S, Levy D, Ehrt S. Expression of many immunologically important genes in Mycobacterium tuberculosis-infected macrophages is independent of both TLR2 and TLR4 but dependent on IFN- α receptor and STAT1. *Journal of immunology*. 2005;175(5):3318-28. doi: 10.4049/jimmunol.175.5.3318. PubMed PMID: 16116224.
 41. Rodriguez ME, Loyd CM, Ding X, Karim AF, McDonald DJ, Canaday DH, et al. Mycobacterial phosphatidylinositol mannoside 6 (PIM6) up-regulates TCR-triggered HIV-1 replication in CD4+ T cells. *PloS one*. 2013;8(11):e80938. doi: 10.1371/journal.pone.0080938. PubMed PMID: 24282561; PubMed Central PMCID: PMC3839890.
 42. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. *Developmental cell*. 2006;10(6):839-50. doi: 10.1016/j.devcel.2006.04.002. PubMed PMID: 16740485.
 43. Rajaiah R, Perkins DJ, Ireland DD, Vogel SN. CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(27):8391-6. doi: 10.1073/pnas.1424980112. PubMed PMID: 26106158; PubMed Central PMCID: PMC4500272.

44. Zanoni I, Ostuni R, Marek LR, Barresi S, Barbalat R, Barton GM, et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. *Cell*. 2011;147(4):868-80. doi: 10.1016/j.cell.2011.09.051. PubMed PMID: 22078883; PubMed Central PMCID: PMC3217211.
45. Motoi Y, Shibata T, Takahashi K, Kanno A, Murakami Y, Li X, et al. Lipopeptides are signaled by Toll-like receptor 1, 2 and 6 in endolysosomes. *International immunology*. 2014;26(10):563-73. doi: 10.1093/intimm/dxu054. PubMed PMID: 24860120.
46. Scumpia PO, Botten GA, Norman JS, Kelly-Scumpia KM, Spreafico R, Ruccia AR, et al. Opposing roles of Toll-like receptor and cytosolic DNA-STING signaling pathways for *Staphylococcus aureus* cutaneous host defense. *PLoS pathogens*. 2017;13(7):e1006496. doi: 10.1371/journal.ppat.1006496. PubMed PMID: 28704551; PubMed Central PMCID: PMC5526579.
47. Eriksson I, Waster P, Ollinger K. Restoration of lysosomal function after damage is accompanied by recycling of lysosomal membrane proteins. *Cell death & disease*. 2020;11(5):370. Epub 2020/05/16. doi: 10.1038/s41419-020-2527-8. PubMed PMID: 32409651; PubMed Central PMCID: PMC7224388.
48. Westman J, Moran G, Mogavero S, Hube B, Grinstein S. *Candida albicans* Hyphal Expansion Causes Phagosomal Membrane Damage and Luminal Alkalinization. *mBio*. 2018;9(5). doi: 10.1128/mBio.01226-18. PubMed PMID: 30206168; PubMed Central PMCID: PMC6134096.
49. Tan T, Lee WL, Alexander DC, Grinstein S, Liu J. The ESAT-6/CFP-10 secretion system of *Mycobacterium marinum* modulates phagosome maturation. *Cellular microbiology*. 2006;8(9):1417-29. doi: 10.1111/j.1462-5822.2006.00721.x. PubMed PMID: 16922861.
50. Queval CJ, Song OR, Carralot JP, Saliou JM, Bongiovanni A, Deloison G, et al. *Mycobacterium tuberculosis* Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. *Cell reports*. 2017;20(13):3188-98. doi: 10.1016/j.celrep.2017.08.101. PubMed PMID: 28954234; PubMed Central PMCID: PMC5637157.
51. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome biology*. 2006;7(10):R100. doi: 10.1186/gb-2006-7-10-r100. PubMed PMID: 17076895; PubMed Central PMCID: PMC1794559.
52. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. *Nature*. 2008;456(7222):658-62. doi: 10.1038/nature07405. PubMed PMID: 18820679; PubMed Central PMCID: PMC2596276.
53. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. *Nature immunology*. 2008;9(12):1407-14. doi: 10.1038/ni.1669. PubMed PMID: 18931679; PubMed Central PMCID: PMC2735466.
54. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, et al. Infection by *Mycobacterium tuberculosis* promotes human alveolar macrophage apoptosis. *Infection and immunity*. 1997;65(1):298-304. Epub 1997/01/01. doi: 10.1128/iai.65.1.298-304.1997. PubMed PMID: 8975927; PubMed Central PMCID: PMC174591.
55. Danelishvili L, McGarvey J, Li YJ, Bermudez LE. *Mycobacterium tuberculosis* infection causes different levels of apoptosis and necrosis in human macrophages and alveolar epithelial cells. *Cellular microbiology*. 2003;5(9):649-60. Epub 2003/08/20. doi: 10.1046/j.1462-5822.2003.00312.x. PubMed PMID: 12925134.
56. Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, et al. A major role for ferroptosis in *Mycobacterium tuberculosis*-induced cell death and tissue necrosis. *The Journal of experimental medicine*. 2019;216(3):556-70. Epub 2019/02/23. doi:

- 10.1084/jem.20181776. PubMed PMID: 30787033; PubMed Central PMCID: PMC6400546.
57. Derrick SC, Morris SL. The ESAT6 protein of *Mycobacterium tuberculosis* induces apoptosis of macrophages by activating caspase expression. *Cellular microbiology*. 2007;9(6):1547-55. Epub 2007/02/15. doi: 10.1111/j.1462-5822.2007.00892.x. PubMed PMID: 17298391.
 58. Rojas M, Barrera LF, Puzo G, Garcia LF. Differential induction of apoptosis by virulent *Mycobacterium tuberculosis* in resistant and susceptible murine macrophages: role of nitric oxide and mycobacterial products. *Journal of immunology*. 1997;159(3):1352-61. Epub 1997/08/01. PubMed PMID: 9233632.
 59. Drennan MB, Nicolle D, Quesniaux VJ, Jacobs M, Allie N, Mpagi J, et al. Toll-like receptor 2-deficient mice succumb to *Mycobacterium tuberculosis* infection. *The American journal of pathology*. 2004;164(1):49-57. doi: 10.1016/S0002-9440(10)63095-7. PubMed PMID: 14695318; PubMed Central PMCID: PMC1602241.
 60. McBride A, Bhatt K, Salgame P. Development of a secondary immune response to *Mycobacterium tuberculosis* is independent of Toll-like receptor 2. *Infection and immunity*. 2011;79(3):1118-23. Epub 2010/12/22. doi: 10.1128/IAI.01076-10. PubMed PMID: 21173309; PubMed Central PMCID: PMC3067489.
 61. McBride A, Konowich J, Salgame P. Host defense and recruitment of Foxp3(+) T regulatory cells to the lungs in chronic *Mycobacterium tuberculosis* infection requires toll-like receptor 2. *PLoS pathogens*. 2013;9(6):e1003397. Epub 2013/06/21. doi: 10.1371/journal.ppat.1003397. PubMed PMID: 23785280; PubMed Central PMCID: PMC3681744.
 62. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to *Mycobacterium tuberculosis*. *The Journal of experimental medicine*. 2005;202(12):1715-24. Epub 2005/12/21. doi: 10.1084/jem.20051782. PubMed PMID: 16365150; PubMed Central PMCID: PMC2212963.
 63. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, Goyert S, et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with *Mycobacterium tuberculosis*. *Journal of immunology*. 2002;169(7):3480-4. PubMed PMID: 12244136.
 64. Brandt KJ, Fickentscher C, Kruithof EK, de Moerloose P. TLR2 ligands induce NF-kappaB activation from endosomal compartments of human monocytes. *PLoS one*. 2013;8(12):e80743. doi: 10.1371/journal.pone.0080743. PubMed PMID: 24349012; PubMed Central PMCID: PMC3861177.
 65. Cambier CJ, Takaki KK, Larson RP, Hernandez RE, Tobin DM, Urdahl KB, et al. *Mycobacteria* manipulate macrophage recruitment through coordinated use of membrane lipids. *Nature*. 2014;505(7482):218-22. doi: 10.1038/nature12799. PubMed PMID: 24336213; PubMed Central PMCID: PMC3961847.
 66. Madan-Lala R, Peixoto KV, Re F, Rengarajan J. *Mycobacterium tuberculosis* Hip1 dampens macrophage proinflammatory responses by limiting toll-like receptor 2 activation. *Infection and immunity*. 2011;79(12):4828-38. doi: 10.1128/IAI.05574-11. PubMed PMID: 21947769; PubMed Central PMCID: PMC3232659.
 67. Blanc L, Gilleron M, Prandi J, Song OR, Jang MS, Gicquel B, et al. *Mycobacterium tuberculosis* inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(42):11205-10. doi: 10.1073/pnas.1707840114. PubMed PMID: 28973928; PubMed Central PMCID: PMC5651758.
 68. Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR, Jr., Ernst JD. Potent inhibition of macrophage responses to IFN-gamma by live virulent *Mycobacterium tuberculosis* is independent of mature mycobacterial lipoproteins but dependent on TLR2. *Journal of*

- immunology. 2006;176(5):3019-27. Epub 2006/02/24. doi: 10.4049/jimmunol.176.5.3019. PubMed PMID: 16493060.
69. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, et al. New use of BCG for recombinant vaccines. *Nature*. 1991;351(6326):456-60. Epub 1991/06/06. doi: 10.1038/351456a0. PubMed PMID: 1904554.
70. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, et al. Identification of host-targeted small molecules that restrict intracellular *Mycobacterium tuberculosis* growth. *PLoS pathogens*. 2014;10(2):e1003946. doi: 10.1371/journal.ppat.1003946. PubMed PMID: 24586159; PubMed Central PMCID: PMC3930586.
71. Zenkova DK, V.; Artyomov, M.; Sergushichev, A. phantasus: Visual and interactive gene expression analysis 2019. Available from: <https://genome.ifmo.ru/phantasus>.

Figures




Figure 1. Macrophage infection with *Mtb* PDIM or ESX-1 mutants reveals two subclusters of genes differentially expressed relative to infection with wild-type *Mtb*.

(A-C) C57BL/6J BMDM were infected with wild-type *Mtb* H37Rv (“WT”), the ESX-1 core complex mutant *Tn::eccCa1* (“E”), or the PDIM production mutant Δmas (“P”) at an MOI of 2:1. At 4, 8, 12, and 16 hours post-infection, RNA was harvested for RNAseq. Sequencing libraries not passing QC metrics were excluded from further analysis. (A) Genes were clustered based on similarity of expression in response to WT *Mtb*. (B, C) Cluster 1 genes from A were subclustered based on the response to WT *Mtb* and the mutants. Uninfected, 12h, and 16h timepoints shown. (A-C) Blue-red gradient reflects relative expression within each row. (D) Volcano plots for the indicated conditions. TNF and co-regulated gene NFKbiz and subcluster 1B genes *saa3*, MARCO, *Icn2* are indicated on each graph. RNAseq experiment performed once.




Figure 2. Infection with Mtb PDIM or ESX-1 mutants elicits enhanced expression of an inflammatory transcriptional program.

(A) fpkm from RNAseq data (MOI 2:1) for representative genes from subcluster 1B. * p-value < 0.01 or # p-value < 0.05 for the comparison of PDIM (16h) or ESX-1 (12h) mutant-infected with Rv-infected, unpaired two-tailed t-test. (B) C57BL/6J BMDM were infected with the indicated strains at an MOI of 10:1. RNA was harvested at the indicated timepoints, and expression of the indicated genes was profiled by qPCR relative to GAPDH control. (C-D) C57BL/6J BMDM were infected with the indicated Mtb strains at an MOI of 2:1. RNA was harvested 24 hours post-infection, and expression of the indicated genes relative to GAPDH control was profiled using qPCR. (B-D) Mean +/- SD of 4 replicates. *p-value < 0.01, **p-value < 0.001, ***p-value < 0.0001 unpaired two-tailed t-test. RNAseq experiment (A) performed once, (B) one of two independent experiments (C-D) one of three independent experiments.




Figure 3. The identified two-component inflammatory response to Mtb is dependent upon MYD88 and TLR2.

(A-B) The indicated BMDM were infected with the indicated Mtb strains at an MOI of 2:1. RNA was harvested 24 hours post-infection. (C-D) C57BL/6J BMDM were infected with the indicated Mtb strains at an MOI of 2:1 (C) or 10:1 (D). RNA was harvested at the indicated timepoints post-infection. (E) The indicated BMDM were infected with the indicated Mtb strains at an MOI of 5:1. RNA was harvested 6 hours after infection. (F-G) The indicated (F) or C57BL/6J (G) BMDM were infected with the indicated Mtb strains at an MOI of 5:1. Supernatants were harvested 24 hours post-infection, and TNF was quantified by ELISA. Mean \pm SD of 4 replicates. *p-value < 0.01, ***p-value < 0.0001 unpaired two-tailed t-test. (A, C, E) one of three independent experiments (B, D, F-G) one of two independent experiments.




Figure 4. The two-component response is a fundamental feature of TLR2 activation.

C57BL/6J (A-B) or the indicated (C-F) BMDM were treated with PAM3CSK 1 μ g/ml (A-D) or PIM6 1 μ g/ml (E-F) and RNA was harvested at the indicated timepoints (A-B), 2 hours (C, E), or 24 hours (D, F). qPCR was performed to quantitate expression of the indicated genes relative to GAPDH control. Mean \pm SD for 4 replicates. **p-value < 0.001, ***p-value < 0.0001 unpaired two-tailed t-test. (A-B) one of two independent experiments, (C-F) one of three independent experiments.




Figure 5

Figure 5. The later component of the TLR2-dependent transcriptional response requires endosomal uptake.

Where indicated, C57BL/6J BMDM were pre-treated with dynasore 80µM or cytochalasin D 10µM. Cells were then treated with PAM3CSK4 1ug/ml (A-B) or infected with the indicated Mtb strains at an MOI of 5:1 (C) or 2:1 (D-E). RNA was harvested at 2 hours (A) 6 hours (C) or 24 hours (B,D-E). qPCR was performed to quantitate expression of the indicated genes relative to GAPDH control. (E, F) BMDM were infected with the indicated Mtb strains at an MOI of 5:1. Supernatants were harvested 24 hours post-infection, and TNF was quantified by ELISA. Mean +/- SD for 4 replicates. #p-value < 0.05, *p-value < 0.01, ***p-value < 0.0001 unpaired two-tailed t-test. (A-E) one of three independent experiments, (F) one of two independent experiments.




Figure 6. Full activation of the endosome-specific TLR2 response is dependent upon phagosome acidification.

(A) The indicated Mtb strains expressing GFP were labeled with pHrodo and used to infect C57BL/6J BMDM at an MOI of 3:1. After 4 hours, cells were washed to remove extracellular bacteria. Cells were fixed at 6, 12, and 24 hours post-infection and imaged. Bacteria were identified based on GFP signal, and pHrodo mean fluorescence intensity was measured around each bacterium. A minimum of 1703 bacteria were analyzed per group. (B-C) C57BL/6J BMDM were pretreated with concanamycin A 50 μ M, then infected with the indicated Mtb strains at an MOI of 5:1 (B) or 2:1 (C). (C, D) C57BL/6J BMDM were pretreated with concanamycin A 50 μ M, then stimulated with PAM3CSK4 1 μ g/ml. RNA was harvested at 6 hours (B), 24 hours (C, E) or 2 hours (D) post-infection. qPCR was performed to quantitate expression of the indicated genes relative to GAPDH control. Mean \pm SD for 4 replicates. # p-value < 0.03, * p-value < 0.01, ** p-value < 0.001, ***p-value < 0.0001, unpaired two-tailed t-test. (A-E) one of three independent experiments.




Figure 7. PDIM and ESX modulate TLR2-dependent infection outcomes in macrophages and mice.

(A-C) The indicated BMDM were infected with the indicated Mtb strains at an MOI of 5:1 (A-B) or 2:1 (C). (A-B) Cell survival was determined using a CellTiterGlo luminescence assay at the indicated days post-infection. (C) At day 5 post-infection, cells were washed, lysed, and plated for CFU. (A-C) Mean \pm SD for 4 replicates. #p-value < 0.05, *p-value < 0.01 unpaired two-tailed t-test. (D) C57BL/6J or TLR2^{-/-} mice were infected with ~200cfu of the indicated Mtb strains. 42 days post-infection, mice were euthanized and lungs were harvested and plated in serial dilutions to determine CFU Mean \pm SD for 5 mice per condition (one C57BL6/ppsD plate discarded for mold contamination- 4 replicates for that condition). #p-value < 0.05, unpaired two-tailed t-test. (A-C) one of three independent experiments (D) one of two independent experiments.